title: Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftment.
authors.affiliation: Department of Medicine, Division of Hematology, Center for Cellular and Molecular Therapy, University of Liège, Liège, Belgium. F.Baron@ulg.ac.be
authors.forename: Frédéric
authors.initials: F
authors.lastname: Baron
authors.forename: Pascale
authors.initials: P
authors.lastname: Frère
authors.forename: Yves
authors.initials: Y
authors.lastname: Beguin
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage* / Q000096:biosynthesis / Q000627:therapeutic use; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011994:Recombinant Proteins; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin